HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

YM 75466

structure in first source

Also Known As:

(N-(4-((1-acetimidoyl--4-piperidyl)oxy)phenyl)-N-((7-amidino-2-naphthyl)methyl)sulfamoyl)acetic acid monomethanesulfonate; YM-75466

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - YM 75466: 2
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - YM 75466: 2
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - YM 75466: 2

Related Diseases

1.	Thromboembolism 10/01/1998 - "In a thromboplastin-induced thromboembolism model, administration of 30 mg/kg YM-75466 or 3 mg/kg warfarin significantly improved the lethality ratio. "
2.	Hemorrhage 10/01/1998 - "In conclusion, this study shows that YM-75466 has advantages over warfarin: i) rapid onset of anticoagulant activity, ii) wide therapeutic range, iii) little effect on bleeding and iv) lack of drug interaction with agents that interfere with warfarin. "
3.	Venous Thrombosis (Deep-Vein Thrombosis) 07/03/1998 - "In the venous thrombosis model, YM-75466 and warfarin inhibited thrombus formation dose-dependently, with ID50 values of 3.3 and 0.56 mg/kg, respectively. "
4.	Thrombosis (Thrombus) 07/03/1998 - "In the venous thrombosis model, YM-75466 and warfarin inhibited thrombus formation dose-dependently, with ID50 values of 3.3 and 0.56 mg/kg, respectively. "

Related Drugs and Biologics

1.	Warfarin (Coumadin)
2.	Thromboplastin (Tissue Factor)
3.	Anticoagulants